tm logo
BEXIGNUS
Live/Registered
REGISTERED

on 30 Apr 2024

Last Applicant/ Owned by

FI-20520 Turku

FI

Serial Number

79350059 filed on 12th Aug 2022

Registration Number

7369451 registered on 30th Apr 2024

in the Principal Register

Correspondent Address

Mark E. Olds

Mark E. Olds Muncy, Geissler, Olds & Lowe, P.C.

Alexandria, VA 22314

UNITED STATES

Filing Basis

1. filing basis filed as 66 a

Disclaimer

NO DATA

BEXIGNUS

Pharmaceuticals used for the prevention and treatment of cancer, bone marrow dysfunction or suppressions, hematological malignancies, immunosystem related diseases and disorders, and diseases of chronic infections in human tissue of an individual; Medical preparations, namely, preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressio Read More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceuticals used for the prevention and treatment of cancer, bone marrow dysfunction or suppressions, hematological malignancies, immunosystem related diseases and disorders, and diseases of chronic infections in human tissue of an individual; Medical preparations, namely, preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders; Sanitary preparations for medical purposes; Pharmaceutical preparations and substances for the treatment of cancer; Tumor suppressing agents; Antineoplastics being preparations and pharmaceutical products for preventing and treating cancer and other immunosystem related diseases and disorders; Anti-cancer preparations; Compounds for treating cancer, namely, pharmaceutical products for the prevention and treatment of cancer; Antibodies for medical use to prevent and treat inflammation and cancer growth and spread, bone marrow dysfunction or suppressions, hematological malignancies, and immunosystem related diseases and disorders; Biological preparations used for immune activation in the prevention and treatment of cancer, immunosystem related diseases and disorders, bone marrow dysfunction or suppressions, hematological malignancies, and chronic infections in human tissue of an individual; Adjuvants for medical purposes; Vaccine adjuvants; Anti-neoplastic preparations of chemical origin being pharmaceutical preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders, and chronic infections; Anti-neoplastic preparations of microbial origin being pharmaceutical preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders, and chronic infections; Antigens, namely, tumour antigens for medical diagnostic purposes and for anti-cancer preparations; Biological preparations for the treatment of cancer; Biopharmaceuticals for the treatment of cancer; Biotechnological preparations for medical use, namely, biological preparations for the treatment of conditions with poor production of hematopoietic stem cells; Biotechnological preparations for medical use, namely, biological preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders, and chronic infections; Immunomodulators, namely, pharmaceutical preparations for restoring and modifying the immune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations for the prevention of disorders of the immune system; Serotherapeutic medicines, namely, pharmaceutical preparations used for immune activation in the treatment of cancer and in the treatment of diseases of chronic infections in human tissue of an individual; Pharmaceutical preparations for immunity adjustment; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for use in hematology


First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details


Serial Number

No 79350059

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 8104.0073TM

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

Yes

66A Current

Yes

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
17th Nov 2024FINAL DECISION TRANSACTION PROCESSED BY IB
26th Oct 2024FINAL DISPOSITION NOTICE SENT TO IB
26th Oct 2024FINAL DISPOSITION PROCESSED
30th Jul 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
30th Apr 2024REGISTERED-PRINCIPAL REGISTER
30th Apr 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
11th Mar 2024NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
21st Feb 2024NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
21st Feb 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
14th Feb 2024NOTIFICATION PROCESSED BY IB